Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
The purpose of this study is to find a dose of intravitreal bevacizumab that is lower than currently used for severe retinopathy of prematurity (ROP), is effective in this study, and can be tested in future larger studies.
Epistemonikos ID: a24d4a292363ccd2b1f1e5369e046150cb495276
First added on: May 12, 2024